Alterity Therapeutics Ltd (AU:ATH) — Market Cap & Net Worth
Market Cap & Net Worth: Alterity Therapeutics Ltd (ATH)
Alterity Therapeutics Ltd (AU:ATH) has a market capitalization of $108.75 Million (AU$153.70 Million) as of August 5, 2026. Listed on the AU stock exchange, this Australia-based company holds position #18858 globally and #596 in its home market, demonstrating a -0.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alterity Therapeutics Ltd's stock price AU$0.56 by its total outstanding shares 10875416329 (10.88 Billion). See ATH capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Alterity Therapeutics Ltd Market Cap History: 2015 to 2026
Alterity Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows growth from $823.37 Million to $4.31 Billion (15.33% CAGR).
Alterity Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alterity Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.32x
Alterity Therapeutics Ltd's market cap is 11.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $353.97 Million | $142.66K | -$7.73 Million | 2481.28x | N/A |
| 2017 | $546.35 Million | $132.40K | -$7.54 Million | 4126.62x | N/A |
| 2018 | $253.94 Million | $201.17K | -$8.27 Million | 1262.27x | N/A |
| 2019 | $153.90 Million | $108.54K | -$11.96 Million | 1417.95x | N/A |
| 2020 | $238.55 Million | $17.12K | -$10.06 Million | 13933.79x | N/A |
| 2021 | $161.60 Million | $4.34 Million | -$15.31 Million | 37.24x | N/A |
| 2022 | $76.95 Million | $5.12 Million | -$12.85 Million | 15.02x | N/A |
| 2023 | $53.87 Million | $3.92 Million | -$13.81 Million | 13.75x | N/A |
| 2024 | $61.56 Million | $4.02 Million | -$19.12 Million | 15.32x | N/A |
| 2025 | $61.56 Million | $5.44 Million | -$12.15 Million | 11.32x | N/A |
Competitor Companies of ATH by Market Capitalization
Companies near Alterity Therapeutics Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to Alterity Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #569 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $478.71 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $760.66 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €728.00 |
| #569 | UCB SA | BR:UCB | $47.34 Billion | €223.30 |
Alterity Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Alterity Therapeutics Ltd's market cap moved from $823.37 Million to $ 4.31 Billion, with a yearly change of 15.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$4.31 Billion | +6900.00% |
| 2025 | AU$61.56 Million | 0.00% |
| 2024 | AU$61.56 Million | +14.29% |
| 2023 | AU$53.87 Million | -30.00% |
| 2022 | AU$76.95 Million | -52.38% |
| 2021 | AU$161.60 Million | -32.26% |
| 2020 | AU$238.55 Million | +55.00% |
| 2019 | AU$153.90 Million | -39.39% |
| 2018 | AU$253.94 Million | -53.52% |
| 2017 | AU$546.35 Million | +54.35% |
| 2016 | AU$353.97 Million | -57.01% |
| 2015 | AU$823.37 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of Alterity Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.75 Million USD |
| MoneyControl | $108.75 Million USD |
| MarketWatch | $108.75 Million USD |
| marketcap.company | $108.75 Million USD |
| Reuters | $108.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more